Outcome After Discontinuation of TNFα-blocking Therapy in Patients with Inflammatory Bowel Disease in Deep Remission

Abstract

After cessation of TNFα-blocking therapy in patients with IBD in deep remission, up to 67% remained in clinical remission during the 12-month follow-up. Importantly, 85% of these patients sustained endoscopic remission. The response to restart of TNFα antagonists was effective and well tolerated.